---
title: "Shanghai Micurx Pharmaceutical Co., Ltd. (688373.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688373.SH.md"
symbol: "688373.SH"
name: "Shanghai Micurx Pharmaceutical Co., Ltd."
industry: "Biotechnology"
datetime: "2026-05-19T17:24:56.885Z"
locales:
  - [en](https://longbridge.com/en/quote/688373.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688373.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688373.SH.md)
---

# Shanghai Micurx Pharmaceutical Co., Ltd. (688373.SH)

## Company Overview

Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resistant gram-negative bacteria; MRX-7 for multidrug-resistant gram-positive bacteria; MRX-15 and MRX-17 to treat kidney disease; MRX-18 for the treatment of COVID-19; and MRX-23 for the treatment of tumour. The company was founded in 2007 and is based in Shanghai, China.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.micurxchina.com](https://www.micurxchina.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:08.000Z

**Overall: D (0.61)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 78 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 15.44% |  |
| Net Profit YoY | 49.67% |  |
| P/B Ratio | 19.12 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3474689215.26 |  |
| Revenue | 150471587.33 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -71.15% | E |
| Profit Margin | -133.74% | E |
| Gross Margin | 85.60% | A |
| Revenue YoY | 15.44% | B |
| Net Profit YoY | 49.67% | B |
| Total Assets YoY | -20.62% | E |
| Net Assets YoY | -52.66% | E |
| Cash Flow Margin | 86.45% | C |
| OCF YoY | 15.44% | B |
| Turnover | 0.20 | D |
| Gearing Ratio | 73.15% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Shanghai Micurx Pharmaceutical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "15.44%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "49.67%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "19.12",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "3474689215.26",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "150471587.33",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-71.15%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-133.74%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "85.60%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "15.44%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "49.67%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-20.62%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-52.66%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "86.45%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "15.44%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.20",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "73.15%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -17.04 | 53/81 | - | - | - |
| PB | 18.86 | 77/81 | 18.81 | 15.84 | 13.54 |
| PS (TTM) | 22.79 | 75/81 | 37.89 | 31.32 | 28.97 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2025-03-23T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 5.23 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688373.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688373.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688373.SH/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**